Comparison · NCT01183104-a6a8df34
Sitagliptin vs Glimepiride: The Number of Participants Achieving HbA1c < 6.9 %
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sitagliptin vs Glimepiride: The Number of Participants Achieving HbA1c < 6.9 %. Trial comparisons, record NCT01183104-a6a8df34. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01183104-a6a8df34
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.664 | 0.581 | 0.739 | wilson | |
| Risk in group 2 | 0.672 | 0.587 | 0.747 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0077 | -0.12 | 0.105 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.989 | 0.833 | 1.17 | log | |
| Odds ratio, group 1 over group 2 | 0.966 | 0.577 | 1.62 | log | |
| Number needed to treat, for one fewer participant with the outcome on Sitagliptin than on Glimepiride | 130 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sitagliptin | Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; eGFR 30=\< \<50). | 89 | 134 | OG000 |
| Group 2 | Glimepiride | Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg | 86 | 128 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Number of Participants Achieving HbA1c < 6.9 %
- Description
- Time frame
- 52 W
- Population
- Analysis set of evaluation for efficacy; Per Protocol Set Some participants were not completed to 52 W.
Source ClinicalTrials.gov
Trial
- Title
- START-J: SiTAgliptin in eldeRly Trial in Japan
- NCT number
- NCT01183104
- Phases
- NA
- Conditions
- Type 2 Diabetes
- Interventions
- Sitagliptin, Glimepiride
- Lead sponsor
- Japan Association for Diabetes Education and Care
- Results first posted
- 2017-04-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01183104?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01183104-a6a8df34